GEHC Introduces LOGIQ Ultrasound Systems Powered by AI to Enhance Imaging and Streamline Workflow

GE HealthCare Launches Advanced LOGIQ Ultrasound Systems

GE HealthCare Technologies Inc. (GEHC) has unveiled its latest LOGIQ general imaging ultrasound portfolio, aiming to deliver superior image clarity, simplify clinical workflows, and boost diagnostic accuracy. The new range—comprising the LOGIQ E10 Series, LOGIQ Fortis, and LOGIQ Totus—features Verisound Digital technology and artificial intelligence enhancements, offering improved imaging capabilities for a variety of medical uses.

These upgraded systems combine enhanced imaging with a flexible digital platform, supporting efficient operations and reliable clinical decision-making. The new LOGIQ lineup will be officially presented at the European Congress of Radiology 2026 in Vienna.

According to company leadership, ongoing innovation in ultrasound is essential for meeting the changing demands of healthcare professionals. The new LOGIQ systems are designed to increase confidence in diagnoses, streamline productivity, and deliver precise results across a wide spectrum of clinical needs—from routine exams to complex liver and abdominal assessments. The systems are built to help clinicians quickly transition from image capture to actionable insights, while remaining adaptable for future technological progress.

Impact on GEHC Stock Performance

After the announcement, GEHC shares remained steady at the previous day’s close. Over the past six months, the company’s stock has risen by 13.5%, outperforming the medical-dental supplies industry, which saw a 13% decline. In comparison, the S&P 500 increased by 8.5% during the same period.

Looking ahead, GEHC is well-positioned to benefit from the introduction of its next-generation LOGIQ ultrasound systems. The integration of AI-driven automation, Verisound Digital advancements, and specialized liver assessment tools strengthens the company’s standing in the competitive diagnostic imaging market. With global imaging volumes on the rise and fatty liver disease becoming more prevalent, these new systems address critical clinical needs while reducing scan times and system interactions. Showcasing these innovations at the European Congress of Radiology 2026 is expected to boost visibility, encourage adoption, and drive revenue growth worldwide.

GEHC’s current market capitalization stands at $38.31 billion.

Image Source: Zacks Investment Research

Details on the LOGIQ Portfolio Expansion

GEHC is broadening the clinical scope of its new LOGIQ ultrasound systems, which are both 510(k) cleared and CE Marked. The expanded portfolio includes a wider selection of transducers, such as specialty and multipurpose probes and the wireless Vscan Air, all designed to enhance image quality and diagnostic accuracy across various care environments.

Liver disease is a major focus, with nearly 40% of the global population affected by fatty liver. The demand for reliable, early-stage diagnostic tools is growing. GEHC positions LOGIQ as a leading solution for liver evaluation, introducing the Ultrasound-Guided Fat Fraction tool for improved liver fat assessment. This feature supports earlier detection, better disease monitoring, and more informed treatment decisions, especially for metabolic dysfunction-associated fatty liver disease.

The latest upgrades include the Auto Abdominal Suite 2.0 with SmartEdit, featuring tools like Auto Abdominal Color Assistant 2.0, Auto Aorta Measure Assistant, and Auto CBD Measure Assistant. These innovations are designed to identify anatomy, improve measurement precision, and minimize system interactions. When used with Scan Assistant, the system has demonstrated up to 65% faster measurements and 80% fewer user interactions.

Additionally, GEHC is enhancing the LOGIQ digital platform to support integration with third-party applications alongside its Verisound Digital solutions. The platform also offers on-scanner ViewPoint reporting for efficient documentation and data management, enabling more connected workflows, easier customization, and consistent, data-driven clinical reporting.

Market Outlook for AI in Ultrasound Imaging

The global market for artificial intelligence in ultrasound imaging is projected to reach $1.22 billion by 2026, with an expected compound annual growth rate of 8.4% through 2035.

Market growth is fueled by factors such as the increasing prevalence of chronic and lifestyle-related diseases, strong worldwide demand for ultrasound imaging, the adoption of AI to improve accuracy and automate workflows, and the rising need for imaging biomarkers and quantitative imaging solutions.

Recent Developments at GE HealthCare

GE HealthCare has recently received FDA 510(k) clearance for three new MRI technologies: SIGNA Sprint with Freelium (a 1.5T sealed magnet system), SIGNA Bolt (a high-performance 3T scanner), and SIGNA One (an AI-powered workflow platform that streamlines MRI processes from setup to post-processing).

The company also announced a $35 million contract expansion with the Biomedical Advanced Research and Development Authority (BARDA), primarily funded by BARDA, to accelerate the development of AI-enabled ultrasound and next-generation imaging solutions for trauma and emergency preparedness.

In the U.S., GE HealthCare introduced ReadyFix, a remote fleet management platform designed to maximize medical device uptime and operational efficiency across healthcare systems. Integrated with the MAC VU360 resting ECG workstations, ReadyFix enables reliable ECG measurements and real-time connectivity for remote diagnostics, repairs, and proactive maintenance.

GE HealthCare Technologies Inc. Price Information

GE HealthCare Technologies Inc. price | GE HealthCare Technologies Inc. Quote

GEHC’s Zacks Rank and Other Top Medical Stocks

GEHC currently holds a Zacks Rank #2 (Buy).

Other highly ranked stocks in the medical sector include Intuitive Surgical (ISRG), Veracyte (VCYT), and Cardinal Health (CAH).

• Intuitive Surgical (ISRG): Currently rated Zacks Rank #1 (Strong Buy), the company reported Q4 2025 adjusted EPS of $2.53, exceeding estimates by 12.4%. Revenue reached $2.87 billion, 4.7% above expectations. ISRG’s projected long-term earnings growth rate is 15.7%, outpacing the industry’s 13.5%. The company has surpassed earnings estimates in the last four quarters, with an average surprise of 13.2%.
• Veracyte (VCYT): With a Zacks Rank #2, Veracyte posted Q3 2025 adjusted EPS of 51 cents, beating estimates by 59.4%. Revenue was $131.8 million, 5.5% above consensus. VCYT’s estimated earnings recession rate for 2026 is 3%, compared to the industry’s 16% growth. The company has exceeded earnings estimates in the past four quarters, with an average surprise of 45.1%.
• Cardinal Health (CAH): Also rated Zacks Rank #2, Cardinal Health reported Q2 fiscal 2026 adjusted EPS of $2.63, 10% above estimates. Revenue was $65.6 billion, 0.9% higher than expected. CAH’s projected long-term earnings growth rate is 15%, compared to the industry’s 9.4%. The company has beaten earnings estimates in the last four quarters, with an average surprise of 9.3%.

Zacks Top 10 Stocks for 2026

There’s still time to access Zacks’ top 10 stock picks for 2026, selected by Director of Research Sheraz Mian. Since 2012, this portfolio has delivered a remarkable +2,530.8% return, far surpassing the S&P 500’s +570.3% gain.

Sheraz Mian has reviewed 4,400 companies covered by the Zacks Rank and chosen the top 10 to buy and hold in 2026. Be among the first to discover these newly released stocks with significant growth potential.

See New Top 10 Stocks >>

For the latest stock recommendations from Zacks Investment Research, you can download the 7 Best Stocks for the Next 30 Days. Click here for this free report.

• Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report
• Cardinal Health, Inc. (CAH): Free Stock Analysis Report
• Veracyte, Inc. (VCYT): Free Stock Analysis Report
• GE HealthCare Technologies Inc. (GEHC): Free Stock Analysis Report

This article was originally published by Zacks Investment Research.

Zacks Investment Research